Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

CVS Health Corp. closed $24.83 short of its 52-week high ($83.25), which the company reached on January 8th.

CVS trades below 9x forward PE, indicating it’s priced for further deterioration, but historically and relatively cheap vs.

Cigna may have the edge with smaller footprint and focused approach, but all three giants face risks from FTC's lawsuit over inflated insulin prices.

The latest trading day saw CVS Health (CVS) settling at $58.40, representing a -0.03% change from its previous close.

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

CVS Health Corp (CVS) stock saw a modest uptick, ending the day at $58.42 which represents a slight increase of $0.59 or 1.02% from the prior close of $57.83. The stock opened at $57.88 and touched a ...

While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that AI stocks hold great ...

CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is ...

CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth ...